Illumina Inc (ILMN)

NASDAQ
Currency in USD
101.09
+0.85(+0.85%)
Closed
After Hours
101.49+0.40(+0.40%)
ILMN Scorecard
Full Analysis
Net income is expected to grow this year
Fair Value
Day's Range
99.33103.04
52 wk Range
97.27156.66
Key Statistics
Edit
Prev. Close
100.24
Open
100
Day's Range
99.33-103.04
52 wk Range
97.27-156.66
Volume
2.92M
Average Volume (3m)
2.27M
1-Year Change
-27.47%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ILMN Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
147.56
Upside
+45.97%
Members' Sentiments
Bearish
Bullish
ProTips
11 analysts have revised their earnings downwards for the upcoming period
Show more

Illumina Inc Company Profile

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Illumina Inc SWOT Analysis


Genomic Dominance
Illumina maintains leadership in next-generation sequencing despite pricing pressures, with strong consumables growth offsetting instrument sales weakness
NovaSeq X Revolution
Explore Illumina's strategic transition to NovaSeq X, promising threefold cost reduction in sequencing and potential market expansion
Competitive Landscape
Learn how Illumina's focus on total workflow cost and multi-omics applications aims to fend off emerging competition in long-read sequencing
Financial Outlook
Analyst price targets range from $110 to $254, with Illumina targeting high single-digit growth and double-digit EPS CAGR through 2027
Read full SWOT analysis

Illumina Inc Earnings Call Summary for Q3/2024

  • Q3 revenue down 2% YoY to $1.1B; non-GAAP operating margin at 22.6%; EPS at $1.14
  • Sequencing consumables up 7%, instruments down 42%; 58 NovaSeq X Plus placed, total 527
  • 2023 revenue forecast: -3% YoY; 2024 guidance: operating margin 21-21.5%, EPS $4.05-$4.15
  • Acquired Fluent BioSciences; $939M cash on hand; issued $500M debt at lower coupon
  • Targeting high single-digit revenue growth by 2027; focus on operational improvements
Last Updated: 2024/11/05, 10:22
Read Full Transcript

Compare ILMN to Peers and Sector

Metrics to compare
ILMN
Peers
Sector
Relationship
P/E Ratio
0.0x−8.0x−0.7x
PEG Ratio
0.34−0.080.00
Price/Book
0.0x1.6x2.6x
Price / LTM Sales
0.0x3.1x3.1x
Upside (Analyst Target)
21.4%94.2%49.4%
Fair Value Upside
Unlock22.9%8.9%Unlock

Analyst Ratings

13 Buy
10 Hold
2 Sell
Ratings:
25 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 147.56
(+45.97% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -8.15
Dividend Yield
3.10%
Industry Median 0.73%
Annualised payout
3.1051
Paid unevenly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Feb 06, 2025
EPS / Forecast
0.95 / 0.92
Revenue / Forecast
1.10B / 1.07B
EPS Revisions
Last 90 days

FAQ

What Is the Illumina (ILMN) Stock Price Today?

The Illumina stock price today is 101.09

What Stock Exchange Does Illumina Trade On?

Illumina is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Illumina?

The stock symbol for Illumina is "ILMN."

What Is the Illumina Market Cap?

As of today, Illumina market cap is 16.10B.

What is Illumina Earnings Per Share?

The Illumina EPS is -8.15.

What Is the Next Illumina Earnings Date?

Illumina will release its next earnings report on 30 Apr 2025.

From a Technical Analysis Perspective, Is ILMN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.